Aly A. Khan is an assistant professor at the University of Chicago and head of AI/ML research at the Chan Zuckerberg Biohub Chicago. A leader in computational immunology, he uses innovative computational methods and large-scale data to advance our understanding of immune function. His career has focused on applying these computational approaches to develop next-generation therapeutics and diagnostics.
He founded and directed the computational immunology program at the Toyota Technological Institute at Chicago, pioneering computational methods for single-cell immune profiling, including early methods to assemble and lineage-map B-cell receptor sequences from single-cell data that are now widely used. He has bridged his work with industry, overseeing research programs across drug discovery, precision medicine and population health at Merck, Genentech, Tempus and 23andMe. His innovations have contributed to three FDA-approved companion diagnostics currently used in clinical cancer care, and he holds 12 patents.
Khan received his Ph.D. in Computational Biology from Cornell University and the Memorial Sloan Kettering Cancer Center. He is a recipient of the Chan Zuckerberg Biohub Chicago Investigator Award and the NIH DP2 NIAID New Innovator Award.
